Epirus Biopharmaceuticals Company Profile (NASDAQ:EPRS)

About Epirus Biopharmaceuticals (NASDAQ:EPRS)

Epirus Biopharmaceuticals logoEPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EPRS
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.33
  • 200 Day Moving Avg: $1.83
  • 52 Week Range: $0.08 - $6.76
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.31
  • P/E Growth: 0.00
Misc:
  • Average Volume: 2.77 million shs.
  • Beta: 2.52
 

Frequently Asked Questions for Epirus Biopharmaceuticals (NASDAQ:EPRS)

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EPRS."

How were Epirus Biopharmaceuticals' earnings last quarter?

Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) posted its quarterly earnings results on Tuesday, March, 15th. The company reported ($0.63) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. View Epirus Biopharmaceuticals' Earnings History.

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:

  • Robert Ticktin, Senior Vice President, General Counsel, Secretary

How do I buy Epirus Biopharmaceuticals stock?

Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epirus Biopharmaceuticals' stock price today?

One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.15.


MarketBeat Community Rating for Epirus Biopharmaceuticals (NASDAQ EPRS)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:EPRS) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
5/11/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
5/11/2016WedbushDowngradeOutperform -> Neutral$11.00 -> $2.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Earnings by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Earnings History by Quarter for Epirus Biopharmaceuticals (NASDAQ EPRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2016Q415($0.56)($0.63)ViewListenView Earnings Details
11/16/2015Q315($0.51)($0.59)$221.00 millionViewListenView Earnings Details
8/7/2015Q215($0.38)($0.65)ViewN/AView Earnings Details
5/12/2015Q1($0.43)($0.39)ViewN/AView Earnings Details
3/23/2015Q414($0.99)($0.80)ViewN/AView Earnings Details
11/10/2014($0.43)($1.28)ViewN/AView Earnings Details
8/20/2014($1.20)($1.52)ViewN/AView Earnings Details
5/9/2014Q114$0.20($0.15)$9.00 million$1.60 millionViewN/AView Earnings Details
3/13/2014($0.14)($0.29)ViewN/AView Earnings Details
11/4/2013Q313($0.50)($0.46)$3.66 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)($0.08)$2.91 million$3.89 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.07)($0.06)$3.44 million$3.70 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.06)$3.12 million$3.67 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:EPRS)
2017 EPS Consensus Estimate: ($0.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.11)($0.11)($0.11)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Insider Trades by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Institutional Ownership by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Insider Trades by Quarter for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/21/2015Robert TicktinGeneral CounselBuy3,000$3.72$11,160.00View SEC Filing  
12/17/2015Aurentz VincentInsiderBuy2,200$3.43$7,546.00View SEC Filing  
12/16/2015Amit MunshiCEOBuy8,270$2.80$23,156.00View SEC Filing  
12/15/2015Amit MunshiCEOBuy8,069$2.87$23,158.03View SEC Filing  
12/9/2015Amit MunshiCEOBuy13,190$4.07$53,683.30View SEC Filing  
12/9/2015Aurentz VincentInsiderBuy2,800$3.85$10,780.00View SEC Filing  
9/21/2015Amit MunshiCEOBuy10,000$6.19$61,900.00View SEC Filing  
9/18/2015Amit MunshiCEOBuy10,000$5.99$59,900.00View SEC Filing  
2/6/2015Montreux Equity Partners Iv LpMajor ShareholderSell167,316$5.00$836,580.00View SEC Filing  
2/4/2015Montreux Equity Partners Iv LpMajor ShareholderSell52,684$4.98$262,366.32View SEC Filing  
2/4/2015Scott M RocklageDirectorBuy400,000$5.00$2,000,000.00View SEC Filing  
1/26/2015Montreux Equity Partners Iv LpMajor ShareholderSell38,516$6.47$249,198.52View SEC Filing  
1/23/2015Montreux Equity Partners Iv LpMajor ShareholderSell22,530$6.29$141,713.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:EPRS)
Source:

Social

Chart

Epirus Biopharmaceuticals (EPRS) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff